Physician profile
Raju Modi
NPI 1528007143
$3,373.07
in general payments reported to CMS, 2019-2025
29 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $357 · 2021: $223 · 2022: $463 · 2023: $506 · 2024: $666 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $503.92 | 2019-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $458.95 | 2019-2023 | Lexiscan |
| Pfizer INC. | $458.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $226.57 | 2019-2025 | |
| Boston Scientific Corporation | $218.76 | 2022-2025 | General - Therapies, Watchman Flx |
| Medtronic, INC. | $187.78 | 2024-2025 | Ffrangio, Hawkone, Corevalve Evolut R |
| Amgen INC. | $172.37 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $154.51 | 2019-2023 | Xarelto |
| Atricure, INC. | $140.41 | 2023-2025 | Synergy Ablation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.65 | 2019-2023 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $99.68 | 2024 | Arcalyst |
| Novo Nordisk INC | $90.43 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $72.60 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $64.10 | 2022-2023 | Verquvo |
| Abiomed | $62.65 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $58.87 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $58.24 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.68 | 2019-2024 | Lifevest |
| Bridgebio Pharma, INC. | $25.86 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $22.76 | 2019 | |
| Lundbeck LLC | $21.22 | 2019 | |
| Philips North America LLC | $19.48 | 2022 | |
| Abbott Laboratories | $18.92 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.75 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $17.62 | 2025 | Optimizer |
| Glaxosmithkline, LLC. | $16.83 | 2025 | Shingrix |
| Scpharmaceuticals INC. | $16.39 | 2025 | |
| Medtronic Vascular, INC. | $14.01 | 2020 | |
| Preventice Services, LLC | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raju Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.